Early switch from intravenous to oral anti-microbial therapy in infectious diseases

Clin Microbiol Infect. 2023 Sep;29(9):1117-1119. doi: 10.1016/j.cmi.2023.06.021. Epub 2023 Jun 21.

Authors

Parham Sendi¹, Sandra B Nelson², Alex Soriano³, Brad Spellberg⁴

Affiliations

¹ Institute for Infectious Diseases, University of Bern, Bern, Switzerland. Electronic address: parham.sendi@unibe.ch.
² Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Department of Infectious Diseases, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
⁴ Hospital Administration, Los Angeles General Medical Center, Los Angeles, CA, USA.

PMID: 37353077
DOI: 10.1016/j.cmi.2023.06.021

No abstract available

Publication types

Editorial

MeSH terms

Administration, Intravenous
Administration, Oral
Anti-Bacterial Agents* / therapeutic use
Communicable Diseases* / drug therapy
Humans
Infusions, Intravenous

Substances

Anti-Bacterial Agents